Metric: Biotech stock values on a roller coaster ride

The nation's biotech industry continues to rack up some big losses overall, but steadily rising revenues are being ginned by a long lineup of newly approved products. That kind of good-news, bad-news scenario has put biotech stock indexes on a roller coaster ride, says The Washington Post, with big spikes followed by swift drops in values. The latest round of ups and downs has demonstrated yet again that investing in the biotech field can require nerves of steel.

- read this article from The Washington Post for more

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.